Segmental Reporting (by Segment) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2012		Mar. 31, 2011		Dec. 31, 2011
Segment reporting, operating income/(loss)
Product sales	$ 1,106.9		$ 889.3
Royalties	56.3		73.6
Other revenues	8.6		9.3
Total revenues	1,171.8		972.2
Cost of product sales	158.4		124.5	[1]
Research and development	220.3		177.9
Selling, general and administrative ("SG&A")	500.0		402.9	[1]
(Gain)/loss on sale of product rights	(7.2)		1.3
Reorganization costs	0		5.5
Integration and acquisition costs	5.3		(6.4)
Total operating expenses	876.8		705.7
Operating income/(loss)	295.0		266.5
Assets	6,718.3		5,672.8		6,380.2
Long-lived assets	923.3	[2]	873.7	[2]
Capital expenditure on long-lived assets	17.5	[2]	43.9	[2]
Specialty Pharmaceuticals
Segment reporting, operating income/(loss)
Product sales	706.7		616.1
Royalties	42.4		37.5
Other revenues	8.3		7.6
Total revenues	757.4		661.2
Cost of product sales	87.1	[3]	81.8	[4]
Research and development	131.0	[3]	102.7	[4]
Selling, general and administrative ("SG&A")	300.1	[3]	266.6	[4]
(Gain)/loss on sale of product rights	(7.2)		1.3
Reorganization costs			2.3
Integration and acquisition costs	1.6		(6.4)
Total operating expenses	512.6		448.3
Operating income/(loss)	244.8		212.9
Assets	2,463.3		2,548.0
Long-lived assets	126.3	[2]	150.2	[2]
Capital expenditure on long-lived assets	2.1	[2]	4.8	[2]
Human Genetic Therapies
Segment reporting, operating income/(loss)
Product sales	351.4		273.2
Royalties	0		0
Other revenues	0.3		0.4
Total revenues	351.7		273.6
Cost of product sales	61.3	[3]	42.7	[4]
Research and development	86.3	[3]	75.2	[4]
Selling, general and administrative ("SG&A")	104.4	[3]	80.1	[4]
(Gain)/loss on sale of product rights	0		0
Reorganization costs			0
Integration and acquisition costs	0		0
Total operating expenses	252.0		198.0
Operating income/(loss)	99.7		75.6
Assets	1,917.9		1,836.7
Long-lived assets	712.1	[2]	678.8	[2]
Capital expenditure on long-lived assets	13.0	[2]	36.3	[2]
Regenerative Medicine
Segment reporting, operating income/(loss)
Product sales	48.8		0
Royalties	0		0
Other revenues	0		0
Total revenues	48.8		0
Cost of product sales	10.0	[3]	0	[4]
Research and development	3.0	[3]	0	[4]
Selling, general and administrative ("SG&A")	41.7	[3]	0	[4]
(Gain)/loss on sale of product rights	0		0
Reorganization costs			0
Integration and acquisition costs	3.7		0
Total operating expenses	58.4		0
Operating income/(loss)	(9.6)		0
Assets	961.5		0
Long-lived assets	23.2	[2]	0	[2]
Capital expenditure on long-lived assets	0.1	[2]	0	[2]
All Other Segment
Segment reporting, operating income/(loss)
Product sales	0		0
Royalties	13.9		36.1
Other revenues	0		1.3
Total revenues	13.9		37.4
Cost of product sales		[3]	0	[4]
Research and development	0	[3]	0	[4]
Selling, general and administrative ("SG&A")	53.8	[3]	56.2	[4]
(Gain)/loss on sale of product rights	0		0
Reorganization costs			3.2
Integration and acquisition costs			0
Total operating expenses	53.8		59.4
Operating income/(loss)	(39.9)		(22.0)
Assets	1,375.6		1,288.1
Long-lived assets	61.7	[2]	44.7	[2]
Capital expenditure on long-lived assets	$ 2.3	[2]	$ 2.8	[2]

[1] Cost of product sales includes amortization of intangible assets relating to favorable manufacturing contracts of $0.2 million for the three months to March 31, 2012 (2011: $0.4 million). SG&A costs include amortization of intangible assets relating to intellectual property rights acquired of $45.6 million for the three months to March 31, 2012 (2011: $36.1 million).

[2] (2) Long-lived assets comprise all non-current assets (excluding goodwill and other intangible assets, deferred contingent consideration assets, deferred tax assets, investments, income tax receivable and financial instruments).

[3] (1) Depreciation from manufacturing plants ($7.2 million) and amortization of favorable manufacturing contracts ($0.2 million) is included in Cost of product sales; depreciation of research and development assets ($6.4 million) in Research and development; and all other depreciation and amortization ($59.2 million) is included in Selling, general and administrative.

[4] (1) Depreciation from manufacturing plants ($7.7 million) and amortization of favorable manufacturing contracts ($0.4 million) is included in Cost of product sales; depreciation of research and development assets ($4.7 million) is included in Research and development; and all other depreciation, amortization and impairment charges ($50.7 million) is included in Selling, general and administrative.